Welcome to the forefront of conversational AI as we explore the fascinating world of AI chatbots in our dedicated blog series. Discover the latest advancements, applications, and strategies that propel the evolution of chatbot technology. From enhancing customer interactions to streamlining business processes, these articles delve into the innovative ways artificial intelligence is shaping the landscape of automated conversational agents. Whether you’re a business owner, developer, or simply intrigued by the future of interactive technology, join us on this journey to unravel the transformative power and endless possibilities of AI chatbots.
Copyright: Any unauthorized use or reproduction of The Daily Star content for commercial purposes
is strictly prohibited and constitutes copyright infringement liable to legal action.
OpenEvidence, an artificial intelligence (AI) startup described as “ChatGPT for doctors”, has raised new funding that values the company at $12 billion, according to a recent report by CNBC.
The Miami-based company said it had secured $250 million in a financing round led by Thrive Capital and DST. OpenEvidence raised $75 million from Sequoia in February at a valuation of $1 billion before its value increased to $6 billion in October. In less than a year, the company has raised about $700 million from investors including Google’s venture arm, Nvidia, Kleiner Perkins, Craft Ventures and the Mayo Clinic, as per the CNBC report.
Founded in 2022 by Daniel Nadler and Zachary Ziegler, OpenEvidence develops an AI-powered chatbot aimed at helping physicians make clinical decisions at the point of care. Nadler previously founded Kensho Technologies, which was acquired by Standard & Poor’s in 2018 for about $700 million, while Ziegler is a Harvard doctoral student specialising in AI.
Nadler has said the system is trained on information from leading scientific and medical journals rather than the open internet, which he argues reduces the risk of low-quality or misleading health information. He has described the “ChatGPT for doctors” label as a simplification of a product designed for high-stakes medical decision-making.
The company claims its platform is used by more than 40 percent of physicians in the United States, though those figures have not been independently verified.
Earlier this month, OpenAI introduced ChatGPT Health, while Anthropic has rolled out Claude Healthcare. Both products are compliant with US health data privacy regulations and are extensions of existing consumer chatbots.
Copyright: Any unauthorized use or reproduction of The Daily Star content for commercial purposes
is strictly prohibited and constitutes copyright infringement liable to legal action.
